Search results
Results from the WOW.Com Content Network
On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, beating the consensus of $11.69. The company reported sales of $3.72 ...
Yahoo Finance Live examines Regeneron Pharmaceuticals' stock following reports of positive results in its eye treatment drug trials.
On Friday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending ...
Regeneron reported an adjusted profit of $11.56 per share on total revenue of $3.55 billion for the quarter, above analysts' estimates of $10.61 per share and $3.38 billion, according to LSEG data.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
Would a stock split help lead Regeneron Pharmaceuticals shares higher? Skip to main content. Subscriptions; Animals. Business. Entertainment. Fitness. Food. Games ... News. Science & Tech.
Regeneron Pharmaceuticals From a page move : This is a redirect from a page that has been moved (renamed). This page was kept as a redirect to avoid breaking links, both internal and external, that may have been made to the old page name.
Regeneron's shares fell marginally to $961.78 in early trading. The company was looking to expand its oncology portfolio with odronextamab, beyond its lone approved skin cancer drug, Libtayo